BioCentury
ARTICLE | Company News

Allergan drops RORgammaT inhibitor for psoriasis

April 30, 2018 11:15 PM UTC

Allergan plc (NYSE:AGN) terminated development of VTP-43742 to treat psoriasis due to safety signals in a Phase II study, EVP and Chief R&D Officer C. David Nicholson said on the company's 1Q18 earnings call. The candidate is an oral small molecule inhibitor of RAR-related orphan receptor C thymus-specific isoform (RORgammaT; RORgamma2).

Allergan gained VTP-43742 when it acquired Vitae Pharmaceuticals Inc. in 2016 for about $639 million (see BioCentury, Oct. 10, 2016)...